{"id":"odm-203-period-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5095190","moleculeType":"Small molecule","molecularWeight":"375.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE10A is predominantly expressed in medium spiny neurons of the striatum. By inhibiting PDE10A, ODM-203 elevates cAMP and cGMP levels, modulating dopaminergic and glutamatergic neurotransmission. This mechanism is hypothesized to correct imbalances in basal ganglia signaling relevant to movement disorders.","oneSentence":"ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:00.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Huntington's disease"}]},"trialDetails":[{"nctId":"NCT03240445","phase":"PHASE1","title":"Impact of Changing the Dosing Regimen on the PK Profile of ODM-203","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-24","conditions":"Healthy","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ODM-203 (Period 1)","genericName":"ODM-203 (Period 1)","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain. Used for Huntington's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}